These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23043578)

  • 21. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
    Dobelbower MC; Burnett Iii OL; Nordal RA; Nabors LB; Markert JM; Hyatt MD; Fiveash JB
    J Med Imaging Radiat Oncol; 2011 Feb; 55(1):77-81. PubMed ID: 21382192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
    Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
    J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
    Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
    J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
    Scoccianti S; Magrini SM; Ricardi U; Detti B; Buglione M; Sotti G; Krengli M; Maluta S; Parisi S; Bertoni F; Mantovani C; Tombolini V; De Renzis C; Lioce M; Fatigante L; Fusco V; Muto P; Berti F; Rubino G; Cipressi S; Fariselli L; Lupattelli M; Santoni R; Pirtoli L; Biti G
    Neurosurgery; 2010 Aug; 67(2):446-58. PubMed ID: 20644432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
    Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
    Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
    Noël G; Quetin P; Heymann S; Karamanoukian D; Schott R
    Cancer Radiother; 2009 Jan; 13(1):17-23. PubMed ID: 19091619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
    Abrey LE
    Curr Neurol Neurosci Rep; 2005 May; 5(3):167-8. PubMed ID: 15865881
    [No Abstract]   [Full Text] [Related]  

  • 32. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
    Combs SE; Wagner J; Bischof M; Welzel T; Edler L; Rausch R; Wagner F; Zabel-du Bois A; Debus J; Schulz-Ertner D
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):999-1005. PubMed ID: 18258384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
    Sherriff J; Tamangani J; Senthil L; Cruickshank G; Spooner D; Jones B; Brookes C; Sanghera P
    Br J Radiol; 2013 Feb; 86(1022):20120414. PubMed ID: 23385995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
    Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
    Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme.
    Baumann F; Bjeljac M; Kollias SS; Baumert BG; Brandner S; Rousson V; Yonekawa Y; Bernays RL
    J Neurooncol; 2004; 67(1-2):191-200. PubMed ID: 15072467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
    De Sanctis V; Mazzarella G; Osti MF; Valeriani M; Alfó M; Salvati M; Banelli E; Tombolini V; Enrici RM
    Anticancer Drugs; 2006 Sep; 17(8):969-75. PubMed ID: 16940807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
    Daróczi B; Szántó E; Tóth J; Barzó P; Bognár L; Bakó G; Szántó J; Mózes P; Hideghéty K
    Ideggyogy Sz; 2013 Nov; 66(11-12):391-8. PubMed ID: 24555238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
    Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
    Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
    McDonald MW; Shu HK; Curran WJ; Crocker IR
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):130-6. PubMed ID: 20399036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.